The ORR for PF-05280014 was 62.5% weighed against 66.5% for trastuzumab using a RR of ORR of 0.94 (CI 95% 0.842C1.049), that was inside the predefined equivalence margin of 0.8C1.25.24 Furthermore, there have been no notable distinctions between PFS success (median 12.16?a few months for PF-05280014 12.06?a few months for Continue Reading